{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:19:00Z","timestamp":1783052340435,"version":"3.54.6"},"reference-count":53,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2024.2024.0181","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T12:57:23Z","timestamp":1729774643000},"source":"Crossref","is-referenced-by-count":2,"title":["Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, T\u00fcrkiye, and South Africa: Subgroup Analysis from the International, Multi-center, Retrospective BHOLISTIC Study"],"prefix":"10.4274","author":[{"given":"David","family":"Brittain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moosa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaya","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimendra Prithipal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia M","family":"Dreosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubarak","family":"Al-mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Shahzad","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Maghfoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Kalayo\u011flu Be\u015fi\u015fik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Bo\u011fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pinchevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhan","family":"Ferhano\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Hoppe","year":"2020","unstructured":"1. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:755-781.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","unstructured":"2. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31:684-691.","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic score \u22653, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial","volume":"34","author":"Carde","year":"2016","unstructured":"3. Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic score \u22653, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016;34:2028-2036.","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","unstructured":"4. Engert A, Diehl V, Franklin J, Lohri A, D\u00f6rken B, Ludwig WD, Koch P, H\u00e4nel M, Pfreundschuh M, Wilhelm M, Tr\u00fcmper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, M\u00fcller-Hermelink HK, Hasenclever D, L\u00f6ffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548-4554.","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Eichenauer DA, Aleman BMP, Andr\u00e9 M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M; ESMO Guidelines Committee. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv19-iv29.","DOI":"10.1093\/annonc\/mdy080"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/ajh.24792","article-title":"Outcomes of patients with relapsed\/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis","volume":"92","author":"Bair","year":"2017","unstructured":"6. Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR, Loren AW, Schuster SJ, Stadtmauer EA, Svoboda J. Outcomes of patients with relapsed\/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol. 2017;92:879-884.","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis","volume":"24","author":"Bair","year":"2019","unstructured":"7. Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis. Oncologist. 2019;24:955-962.","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1080\/10428194.2017.1421762","article-title":"Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries","volume":"59","author":"Collins","year":"2018","unstructured":"8. Collins GP, Rueda A, Salles G, von Tresckow B, Zaja F. Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries. Leuk Lymphoma. 2018;59:2113-2120.","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.7150\/jca.29308","article-title":"Treatment of relapsed\/refractory Hodgkin lymphoma: real-world data from the Czech Republic and Slovakia","volume":"10","author":"Kr\u00e1l","year":"2019","unstructured":"9. Kr\u00e1l Z, Michalka J, M\u00f3cikov\u00e1 H, Markov\u00e1 J, S\u00fdkorov\u00e1 A, Belada D, Jungov\u00e1 A, Vokurka S, Luk\u00e1\u0161ov\u00e1 M, Proch\u00e1zka V, \u010eura\u0161 J, H\u00e1jek R, Du\u0161ek L, Drgo\u0148a \u013d, Ladick\u00e1 M, Ballov\u00e1 V, Vranovsk\u00fd A. Treatment of relapsed\/refractory Hodgkin lymphoma: real-world data from the Czech Republic and Slovakia. J Cancer. 2019;10:5041-5048.","journal-title":"J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1080\/10428194.2017.1382698","article-title":"Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed\/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany","volume":"59","author":"Zagadailov","year":"2018","unstructured":"10. Zagadailov EA, Corman S, Chirikov V, Johnson C, Macahilig C, Seal B, Dalal MR, Br\u00f6ckelmann PJ, Illidge T. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed\/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk Lymphoma. 2018;59:1413-1419.","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","unstructured":"11. Wilke C, Cao Q, Dusenbery KE, Bachanova V, Lazaryan A, Lee CK, Yuan J. Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017;99:94-102.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.canep.2016.06.004","article-title":"Cancer burden in four countries of the Middle East Cancer Consortium (Cyprus; Jordan; Israel; Izmir (Turkey)) with comparison to the United States surveillance; epidemiology and end results program","volume":"44","author":"Anton-Culver","year":"2016","unstructured":"12. Anton-Culver H, Chang J, Bray F, Znaor A, Stevens L, Eser S, Silverman B, Nimri O, Pavlou P, Charalambous H, Demetriou A, Ward K, Ziogas A. Cancer burden in four countries of the Middle East Cancer Consortium (Cyprus; Jordan; Israel; Izmir (Turkey)) with comparison to the United States surveillance; epidemiology and end results program. Cancer Epidemiol. 2016;44:195-202.","journal-title":"Cancer Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/cam4.597","article-title":"Hematologic malignancies in South Africa 2000-2006: analysis of data reported to the National Cancer Registry","volume":"5","author":"Schonfeld","year":"2016","unstructured":"13. Schonfeld SJ, Erdmann F, Wiggill T, Singh E, Kellett P, Babb C, Sch\u00fcz J. Hematologic malignancies in South Africa 2000-2006: analysis of data reported to the National Cancer Registry. Cancer Med. 2016;5:728-738.","journal-title":"Cancer Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.7314\/APJCP.2015.16.5.2069","article-title":"Changing trends of adult lymphoma in the Kingdom of Saudi Arabia - comparison of data sources","volume":"16","author":"Rauf","year":"2015","unstructured":"14. Rauf MS, Akhtar S, Maghfoor I. Changing trends of adult lymphoma in the Kingdom of Saudi Arabia - comparison of data sources. Asian Pac J Cancer Prev. 2015;16:2069-2072.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1200\/JGO.19.00230","article-title":"Addressing cancer treatment shortages in Saudi Arabia: results of a national survey and expert panel recommendations","volume":"6","author":"AlAzmi","year":"2020","unstructured":"15. AlAzmi AA, Jastaniah W, Alhamdan HS, AlYamani AO, AlKhudhyr WI, Abdullah SM, AlZahrani M, AlSahafi A, AlOhali TA, Alkhelawi T, AlObaida Y, Allam A, Al-Hashmi H, Murshid E, AlNajjar F, AlGethami A, AlHarbi A, AlFoheidi MO, AlSaeed AS, Elsolh H, Abosoudah I, Ben Obaid A, AlNahedh M. Addressing cancer treatment shortages in Saudi Arabia: results of a national survey and expert panel recommendations. JCO Glob Oncol. 2020;6:476-485.","journal-title":"JCO Glob Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jsps.2020.12.005","article-title":"Cancer management in Saudi Arabia: recommendations by the Saudi oncology HeAlth economics expeRt grouP (SHARP)","volume":"29","author":"Alkhudair","year":"2021","unstructured":"16. Alkhudair N, Alshamrani M, Samarkandi H, Almodaheem H, Alabdulkarim H, Alsaqaaby M, Alnajjar F, Alhashem H, Bakkar M, Bazarbashi S, Alnahedh M, Alfraih F, Alawagi M, Al-Jedai A. Cancer management in Saudi Arabia: recommendations by the Saudi oncology HeAlth economics expeRt grouP (SHARP). Saudi Pharm J. 2021;29:115-120.","journal-title":"Saudi Pharm J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1182\/blood-2012-02-387092","article-title":"Meeting the challenge of hematologic malignancies in sub-Saharan Africa","volume":"119","author":"Gopal","year":"2012","unstructured":"17. Gopal S, Wood WA, Lee SJ, Shea TC, Naresh KN, Kazembe PN, Casper C, Hesseling PB, Mitsuyasu RT. Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood. 2012;119:5078-5087.","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1080\/10428194.2022.2126281","article-title":"Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study","volume":"63","author":"Ferhanoglu","year":"2022","unstructured":"18. Ferhanoglu B, Kim TM, Karduss A, Brittain D, Tumyan G, Al-Mansour M, Zerga M, Song Y, Rivas-Vera S, Kwong YL, Lim ST, Yeh SP, Abdillah A, Huang Z, Dalal M, Wan H, Hertzberg M. Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study. Leuk Lymphoma. 2022;63:3317-3330.","journal-title":"Leuk Lymphoma"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4103\/sjmms.sjmms_200_21","article-title":"Survival and epidemiologic trends of lymphomas in Saudi Arabia: a 10-year report from a tertiary care hospital","volume":"10","author":"Altowairqi","year":"2022","unstructured":"19. Altowairqi MY, Alyousef MY, Ghandour MK, Alrashed AA, Aljebrin YJ, Alotheem GA, Aleem A, Algahtani F, Alzahrani MF. Survival and epidemiologic trends of lymphomas in Saudi Arabia: a 10-year report from a tertiary care hospital. Saudi J Med Med Sci. 2022;10:31-35.","journal-title":"Saudi J Med Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000460819","article-title":"Hodgkin lymphoma outcome: a retrospective study from 3 tertiary centers in Saudi Arabia","volume":"40","author":"Shafi","year":"2017","unstructured":"20. Shafi RG, Al-Mansour MM, Kanfar SS, Al Hashmi H, Alsaeed A, Al-Foheidi M, Ibrahim EM. Hodgkin lymphoma outcome: a retrospective study from 3 tertiary centers in Saudi Arabia. Oncol Res Treat. 2017;40:288-292.","journal-title":"Oncol Res Treat"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5455\/gulhane.25722","article-title":"Epidemiology and histological subtypes of Hodgkin lymphoma in the south-west of Turkey","volume":"54","author":"Y\u0131ld\u0131r\u0131m","year":"2012","unstructured":"21. Y\u0131ld\u0131r\u0131m M, Y\u0131ld\u0131z M, Kurto\u011flu E, Karak\u0131l\u0131n\u00e7 H, Dilli UD, G\u00f6kta\u015f S. Epidemiology and histological subtypes of Hodgkin lymphoma in the south-west of Turkey. Gulhane Med J. 2012;54:216-219.","journal-title":"Gulhane Med J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.7196\/SAMJ.2018.v108i7.12844","article-title":"Incidence of Hodgkin lymphoma in HIV-positive and HIV-negative patients at a tertiary hospital in South Africa (2005-2016) and comparison with other African countries","volume":"108","author":"Naidoo","year":"2018","unstructured":"22. Naidoo N, Abayomi A, Locketz C, Musaigwa F, Grewal R. Incidence of Hodgkin lymphoma in HIV-positive and HIV-negative patients at a tertiary hospital in South Africa (2005-2016) and comparison with other African countries. S Afr Med J. 2018;108:563-567.","journal-title":"S Afr Med J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"799948","DOI":"10.3389\/fonc.2021.799948","article-title":"Real-world outcomes of Hodgkin lymphoma: a multi-centric registry from India","volume":"11","author":"Bhurani","year":"2021","unstructured":"23. Bhurani D, Nair R, Rajappa S, Rao SA, Sridharan N, Boya RR, Raman GS, Menon H, Seshachalam A, Nimmagadda R. Real-world outcomes of Hodgkin lymphoma: a multi-centric registry from India. Front Oncol. 2021;11:799948.","journal-title":"Front Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.5306\/wjco.v12.i9.800","article-title":"Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: real-world data from a single center","volume":"12","author":"S\u00e1nchez-Valledor","year":"2021","unstructured":"24. S\u00e1nchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, C\u00f3rdova-Ram\u00edrez AC, Rivera-\u00c1lvarez M, Le\u00f3n-Pe\u00f1a A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Arg\u00fcelles GJ. Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: real-world data from a single center. World J Clin Oncol. 2021;12:800-807.","journal-title":"World J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Althomali M, Absi A, El Hemaidi I, Warsi A, AlAmoudi S, AlAhmadi M, Rajkhan W, Almutairi S, Eldadah S, Khalil M, Adam M, Ali SA, Alghamdi A, Al Saeed A. Brentuximab vedotin plus bendamustine: as salvage regimen for relapsed or refractory Hodgkin lymphoma, King Abdulaziz Medical City-Jeddah-KSA experience. Blood. 2019;134(Suppl 1):5295.","DOI":"10.1182\/blood-2019-121993"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"100276","DOI":"10.1016\/j.lrr.2021.100276","article-title":"Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era","volume":"16","author":"Abuelgasim","year":"2021","unstructured":"26. Abuelgasim KA, Ghazi S, Alahmari B, Alhejazi A, Alaskar A, Alzahrani M, Damlaj M. Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era. Leuk Res Rep. 2021;16:100276.","journal-title":"Leuk Res Rep"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Driessen J, de Wit F, Herrera AF, Zinzani PLL, LaCasce AS, Moskowitz CH, Garcia-Sanz R, Cole PD, Fuchs M, Mueller H, Borchmann P, Sch\u00f6der H, Zijlstra JM, Hutten BA, Moskowitz AJ, Kersten MJ. Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed\/refractory Hodgkin lymphoma: a large multi-trial analysis based on individual patient data. Blood. 2021;138(Suppl 1):879-882.","DOI":"10.1182\/blood-2021-147810"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","unstructured":"28. Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183-1194.","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","unstructured":"29. LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40-48.","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)","volume":"30","author":"Garcia-Sanz","year":"2019","unstructured":"30. Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30:612-620.","journal-title":"Ann Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/diagnostics13010053","article-title":"The role of positron emission tomography and computed tomographic (PET\/CT) imaging for radiation therapy planning: a literature review","volume":"13","author":"Mallum","year":"2022","unstructured":"31. Mallum A, Mkhize T, Akudugu JM, Ngwa W, Vorster M. The role of positron emission tomography and computed tomographic (PET\/CT) imaging for radiation therapy planning: a literature review. Diagnostics (Basel). 2022;13:53.","journal-title":"Diagnostics (Basel)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"100998","DOI":"10.1016\/j.eclinm.2021.100998","article-title":"Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin lymphoma in Sri Lanka","volume":"38","author":"Hewamana","year":"2021","unstructured":"32. Hewamana S, Kandabadage L, Skandarajah T, Peiris N, Abeyaratne S, Arseculeratne G, Perera E, Harischandra M, Wijewickrama A, Somasundaram G, Srinivasan V, Somiah S, Jayawardena P, Wadanamby R, Galagoda G, Jayasinghe C, De Silva C, Munasinghe S, Wijesiriwardena B, Balawardena J. Applicability of protocols from high-income countries in a resource limited setting; real world data of histopathology, clinical features and long-term outcome of Hodgkin lymphoma in Sri Lanka. EClinicalMedicine. 2021;38:100998.","journal-title":"EClinicalMedicine"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bjhh.2017.08.001","article-title":"High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center","volume":"39","author":"Jaime-P\u00e9rez","year":"2017","unstructured":"33. Jaime-P\u00e9rez JC, Gamboa-Alonso CM, Padilla-Medina JR, Jim\u00e9nez-Castillo RA, Olgu\u00edn-Ram\u00edrez LA, Guti\u00e9rrez-Aguirre CH, Cant\u00fa-Rodr\u00edguez OG, G\u00f3mez-Almaguer D. High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center. Rev Bras Hematol Hemoter. 2017;39:325-330.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref33","unstructured":"34. World Health Organization. Global Atlas of Medical Devices. Geneva, WHO, 2017. Available online at https:\/\/apps.who.int\/iris\/handle\/10665\/255181."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.4102\/sajr.v25i1.2201","article-title":"PET-CT in brain disorders: the South African context","volume":"25","author":"Doruyter","year":"2021","unstructured":"35. Doruyter AGG, Parkes J, Carr J, Warwick JM. PET-CT in brain disorders: the South African context. SA J Radiol. 2021;25:2201.","journal-title":"SA J Radiol"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Jacobson CA, Abramson JS. HIV-associated Hodgkin's lymphoma: prognosis and therapy in the era of cART. Adv Hematol. 2012;2012:507257.","DOI":"10.1155\/2012\/507257"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"578163","DOI":"10.1155\/2011\/578163","article-title":"Human immunodeficiency virus infection and Hodgkin's lymphoma in South Africa: an emerging problem","volume":"2011","author":"Patel","year":"2011","unstructured":"37. Patel M, Philip V, Fazel F. Human immunodeficiency virus infection and Hodgkin's lymphoma in South Africa: an emerging problem. Adv Hematol. 2011;2011:578163.","journal-title":"Adv Hematol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/08830185.2014.893301","article-title":"Neutropenia during HIV infection: adverse consequences and remedies","volume":"33","author":"Shi","year":"2014","unstructured":"38. Shi X, Sims MD, Hanna MM, Xie M, Gulick PG, Zheng YH, Basson MD, Zhang P. Neutropenia during HIV infection: adverse consequences and remedies. Int Rev Immunol. 2014;33:511-536.","journal-title":"Int Rev Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12885-019-5586-4","article-title":"The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting","volume":"19","author":"Antel","year":"2019","unstructured":"39. Antel K, Levetan C, Mohamed Z, Louw VJ, Oosthuizen J, Maartens G, Verburgh . The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting. BMC Cancer. 2019;19:384.","journal-title":"BMC Cancer"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Lippman SA, El Ayadi AM, Grignon JS, Puren A, Liegler T, Venter WDF, Ratlhagana MJ, Morris JL, Naidoo E, Agnew E, Barnhart S, Shade SB. Improvements in the South African HIV care cascade: findings on 90-90-90 targets from successive population-representative surveys in North West Province. J Int AIDS Soc. 2019;22:e25295.","DOI":"10.1002\/jia2.25295"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/aje\/kwac006","article-title":"One pill, once a day: simplified treatment regimens and retention in HIV care","volume":"191","author":"Bor","year":"2022","unstructured":"41. Bor J, Kluberg SA, LaValley MP, Evans D, Hirasen K, Maskew M, Long L, Fox MP. One pill, once a day: simplified treatment regimens and retention in HIV care. Am J Epidemiol. 2022;191:999-1008.","journal-title":"Am J Epidemiol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s11764-022-01320-x","article-title":"An analysis of survivorship care strategies in national cancer control plans in Africa","volume":"17","author":"Garton","year":"2023","unstructured":"42. Garton EM, Ali Z, Cira MK, Haskins L, Jacobsen PB, Kayiira A, Lasebikan N, Onyeka T, Romero Y, Shirima S, Tittenbrun Z, Mollica MA. An analysis of survivorship care strategies in national cancer control plans in Africa. J Cancer Surviv. 2023;17:634-645.","journal-title":"J Cancer Surviv"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1200\/JGO.2015.000406","article-title":"Cancer care in Africa: an overview of resources","volume":"1","author":"Stefan","year":"2015","unstructured":"43. Stefan DC. Cancer care in Africa: an overview of resources. J Glob Oncol. 2015;1:30-36.","journal-title":"J Glob Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00277-018-3533-0","article-title":"Hodgkin lymphoma at Groote Schuur Hospital, South Africa: the effect of HIV and bone marrow infiltration","volume":"98","author":"Swart","year":"2019","unstructured":"44. Swart L, Novitzky N, Mohamed Z, Opie J. Hodgkin lymphoma at Groote Schuur Hospital, South Africa: the effect of HIV and bone marrow infiltration. Ann Hematol. 2019;98:381-389.","journal-title":"Ann Hematol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.7196\/SAMJ.2019.v109i10.14360","article-title":"Approach to lymphoma diagnosis and management in South Africa","volume":"109","author":"Verburgh","year":"2019","unstructured":"45. Verburgh E, Antel K. Approach to lymphoma diagnosis and management in South Africa. S Afr Med J. 2019;109:715-718.","journal-title":"S Afr Med J"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/QAI.0000000000002276","article-title":"Brief report: HIV-associated Hodgkin lymphoma involving the bone marrow identifies a very high-risk subpopulation in the era of widescale antiretroviral therapy use in Johannesburg, South Africa","volume":"83","author":"Vaughan","year":"2020","unstructured":"46. Vaughan J, Perner Y, McAlpine E, Wiggill T. Brief report: HIV-associated Hodgkin lymphoma involving the bone marrow identifies a very high-risk subpopulation in the era of widescale antiretroviral therapy use in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2020;83:345-349.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.transci.2016.01.013","article-title":"Hematopoietic cell transplantation activity of Turkey in 2014: ongoing increase in HCT rates","volume":"54","author":"Tekg\u00fcnd\u00fcz","year":"2016","unstructured":"47. Tekg\u00fcnd\u00fcz E, \u015eencan \u0130, Kapua\u011fas\u0131 A, \u00dcnal D, \u00d6zt\u00fcrk M, G\u00fcm\u00fc\u015f E, G\u00f6ker H, Tavil EB, Ertem M, \u00c7etin M, Arat M, Soysal T, Karaka\u015fl\u0131 O, Sur HY, Ye\u015filipek A, Ferhano\u011flu B, U\u00e7kan D, \u0130lhan O, Altunta\u015f F. Hematopoietic cell transplantation activity of Turkey in 2014: ongoing increase in HCT rates. Transfus Apher Sci. 2016;54:53-59.","journal-title":"Transfus Apher Sci"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.healthpol.2015.06.003","article-title":"What have health care reforms achieved in Turkey? An appraisal of the \"Health Transformation Programme\"","volume":"119","author":"\u00d6kem","year":"2015","unstructured":"48. \u00d6kem ZG, \u00c7akar M. What have health care reforms achieved in Turkey? An appraisal of the \"Health Transformation Programme\". Health Policy. 2015;119:1153-1163.","journal-title":"Health Policy"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jtct.2023.04.002","article-title":"Impact of risk factors and long term survival analysis of patients with primary refractory Hodgkin lymphoma who underwent high dose chemotherapy and autologous stem cell transplant","volume":"29","author":"Akhtar","year":"2023","unstructured":"49. Akhtar S, Rauf MS, Elhassan TAM, Khan ZA, Elshenawy MA, Maghfoor I. Impact of risk factors and long term survival analysis of patients with primary refractory Hodgkin lymphoma who underwent high dose chemotherapy and autologous stem cell transplant. Transplant Cell Ther. 2023;29:451.","journal-title":"Transplant Cell Ther"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00277-018-3283-z","article-title":"Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant","volume":"97","author":"Elshenawy","year":"2018","unstructured":"50. Elshenawy MA, Shahzad Rauf M, Elhassan TAM, Maghfoor I, Akhtar S. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant. Ann Hematol. 2018;97:1229-1240.","journal-title":"Ann Hematol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00277-014-2215-9","article-title":"Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey","volume":"94","author":"Salihoglu","year":"2015","unstructured":"51. Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2015;94:415-420.","journal-title":"Ann Hematol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00277-019-03899-1","article-title":"Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience","volume":"99","author":"\u00d6zbalak","year":"2020","unstructured":"52. \u00d6zbalak M, Saliho\u011flu A, Soysal T, Karado\u011fan \u0130, Payda\u015f S, \u00d6zdemir E, Y\u0131ld\u0131z B, Karadurmu\u015f N, Kaynar L, Yagci M, \u00d6zkocaman V, Top\u00e7uo\u011flu P, \u00d6zcan M, Birta\u015f E, G\u00f6ker H, Ferhanoglu B. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. Ann Hematol. 2020;99:301-307.","journal-title":"Ann Hematol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/1120009X.2021.1976912","article-title":"Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients","volume":"34","author":"Uncu Ulu","year":"2022","unstructured":"53. Uncu Ulu B, Dal MS, Y\u00f6nal Hindilerden \u0130, Akay OM, Mehtap \u00d6, B\u00fcy\u00fckkurt N, Hindilerden F, G\u00fcne\u015f AK, Yi\u011feno\u011flu TN, Ba\u015fc\u0131 S, K\u0131z\u0131l \u00c7akar M, Yanarda\u011f A\u00e7\u0131k D, Korkmaz S, Ula\u015f T, \u00d6zet G, Ferhano\u011flu B, Nal\u00e7ac\u0131 M, Altunta\u015f F. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. J Chemother. 2022;34:190-198.","journal-title":"J Chemother"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:55:23Z","timestamp":1733468123000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-27576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":53,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0181","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"value":"1300-7777","type":"print"},{"value":"1308-5263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}